Clinical Research Services
Clinical research serves as the critical bridge between laboratory discoveries and approved therapies, particularly for patients battling rare motor and neurological diseases who have long awaited effective treatment options. At Protheragen, we provide comprehensive clinical research services that address the unique challenges of orphan drug development, delivering a seamless pathway from first-in-human studies through post-marketing support.
Introduction to Clinical Research
Clinical research serves as the vital bridge between groundbreaking scientific discoveries and the delivery of safe, effective therapies to patients. It encompasses a rigorous, multi-phase process designed to evaluate the safety, efficacy, and optimal use of new treatments in humans. For rare movement and neurological disorders, specialized clinical research is not merely beneficial but essential. Given the complex pathophysiology of these conditions and the inherently limited patient populations, traditional research models often prove insufficient. This necessitates a dual approach encompassing both investigator-initiated trials (IITs) , which explore innovative scientific hypotheses and real-world clinical applications, and industry-sponsored trials (ISTs) , which focus on rigorous regulatory validation for drug approval. Together, these complementary frameworks accelerate the development of targeted therapies, ensuring that scientific innovation translates into meaningful treatment options for patients with the most challenging and underserved medical conditions.
Fig.1 The conventional drug development process versus co-clinical trials. (Balasubramanian B, et al., 2021)
Challenges in Clinical Research of Rare Motor and Neurological Diseases
Conducting clinical research in rare motor and neurological diseases presents a unique set of scientific, operational, and regulatory hurdles that distinguish it from conventional drug development. These challenges stem from the complex nature of neurological disorders, the scarcity of patient populations, and the limitations of existing assessment tools.
- Small and Geographically Dispersed Patient Populations: Limited numbers of eligible participants necessitate multi-center international trials, increasing logistical complexity and operational costs.
- Heterogeneity of Disease Presentation: Significant variability in symptoms and disease progression complicates patient stratification and endpoint selection.
- Lack of Established Biomarkers and Clinical Endpoints: The absence of validated biomarkers forces reliance on subjective outcome measures that may obscure true therapeutic benefit.
- Difficulty in Natural History Characterization: Sparse natural history data makes it challenging to distinguish treatment effects from normal disease variability.
- Ethical and Logistical Considerations in Vulnerable Populations: Cognitive impairment and pediatric involvement raise complex issues around informed consent and patient burden.
Our Services
To overcome the inherent challenges of drug development in rare motor and neurological diseases, Protheragen offers comprehensive clinical research services tailored to the unique demands of this specialized field. By integrating deep scientific expertise with operational flexibility, we provide solutions that address patient recruitment difficulties, regulatory complexities, and the need for innovative trial designs. Our services are designed to transform scientific promise into clinical reality, helping sponsors navigate every stage of the clinical development pathway while ensuring data integrity and regulatory compliance.
One-stop Solution for Clinical Research
Protheragen provides a fully integrated one-stop solution for clinical research, offering end-to-end support for both investigator initiated trials (IITs) and industry sponsored trials (ISTs). By consolidating every phase of the clinical development process under one roof, we eliminate the inefficiencies of fragmented vendor management and ensure seamless coordination from study design through to regulatory submission.
Our investigator initiated trial services provide comprehensive support to academic and clinical investigators seeking to explore innovative scientific hypotheses in rare motor and neurological diseases, guiding them through a streamlined workflow from concept to completion.
Scientific Review and Feasibility Assessment
We conduct a thorough evaluation of the proposed study concept, assessing its scientific merit and alignment with current clinical knowledge. A detailed feasibility analysis is performed to identify potential recruitment challenges and operational constraints within the target patient population.
Protocol Development and Regulatory Strategy
Our regulatory and clinical experts collaborate closely with investigators to develop scientifically sound protocols that meet international standards. We manage all aspects of regulatory submissions, including IRB/IEC approvals and competent authority notifications, ensuring compliance with local and global requirements.
Trial Setup and Site Management
We oversee the complete activation of trial sites, including feasibility assessments, site selection, and initiation visits. Contract negotiations, budget management, and essential document collection are handled efficiently to accelerate study startup timelines.
Study Monitoring and Data Management
Dedicated clinical monitors conduct regular site visits to verify data accuracy, ensure protocol adherence, and identify potential issues proactively. Our centralized data management platform enables secure capture, validation, and real-time oversight of trial data throughout the study lifecycle.
Safety Surveillance and Pharmacovigilance
A comprehensive safety management system is implemented to capture, evaluate, and report adverse events in accordance with regulatory requirements. We ensure continuous patient protection through diligent medical monitoring and timely submission of safety updates to relevant authorities.
Statistical Analysis and Final Reporting
Biostatisticians develop customized analysis plans tailored to the study objectives and data characteristics. Upon study completion, we deliver comprehensive final reports, including detailed statistical summaries and interpretation of results to support publication and future research endeavors.
- Industry Sponsored Trial (IST) Services
Protheragen offers comprehensive industry sponsored trial services spanning phase I through phase IV clinical development, providing end-to-end support for sponsors advancing therapies in rare motor and neurological diseases. Our integrated service model encompasses all critical management functions—including regulatory affairs, data management, biostatistics, medical monitoring, pharmacovigilance, and quality assurance—ensuring seamless coordination across every stage of the trial lifecycle.
By Workflow
| Clinical Trial Phase | Description |
|---|---|
| Phase I Clinical Trial | Our dedicated phase I clinical trial center is equipped with 60 inpatient beds, including 2 resuscitation beds, providing a controlled environment for first-in-human studies, dose escalation, and initial safety and tolerability assessments in carefully monitored patient populations. |
| Phase II Clinical Trial | We support proof-of-concept and dose-finding studies through streamlined patient recruitment, specialized efficacy endpoint evaluation, and continuous safety monitoring to determine optimal dosing regimens and preliminary therapeutic signals. |
| Phase III Clinical Trial | Our team manages large-scale, multi-center confirmatory trials with comprehensive global site coordination, robust data management systems, and stringent quality assurance to generate the pivotal efficacy and safety data required for regulatory submissions. |
| Phase IV Clinical Trial | We facilitate post-marketing studies, including long-term safety surveillance, real-world evidence generation, and therapeutic optimization research, helping sponsors fulfill regulatory commitments and expand understanding of product performance in broader patient populations. |
By Management
Medical & Clinical Strategy Services
Comprehensive planning for clinical programs, including product profile optimization, indication prioritization, clinical development design, and regulatory pathway alignment.
IND/NDA/BLA Application Strategy Services
Strategic navigation of regulatory submissions for INDs, NDAs, and BLAs, leveraging rare disease incentives and expedited pathways to accelerate approval timelines.
Preparation of clinical documents including protocols, investigator brochures, study reports, and regulatory dossiers ensuring scientific accuracy and compliance with international standards.
Site Management & Patient Recruitment Services
End-to-end site activation and targeted recruitment strategies addressing the challenges of engaging geographically dispersed rare neurological patient populations.
Data Management & Statistical Analysis Services
Secure data capture systems and biostatistical methodologies ensuring data integrity with advanced techniques appropriate for small sample sizes.
Ongoing clinical oversight including eligibility review, safety assessment, and protocol guidance ensuring patient protection in complex neurological studies.
Safety & Pharmacovigilance Services
Comprehensive adverse event surveillance and reporting systems with attention to long-term safety monitoring requirements for neurological therapies.
Rigorous quality assurance frameworks including audit preparation, CAPA management, and compliance oversight throughout the clinical development lifecycle.
Dedicated single-point coordination of all trial activities ensuring timeline adherence, budget control, and seamless stakeholder communication.
Post-Marketing Study Services
Ongoing support for post-approval commitments including safety registries, real-world evidence generation, and phase IV studies addressing regulatory requirements.
Disease Areas of Focus
| Disease Types | Disease Names | |
| Rare Motor Neuron Diseases (MND) | ||
| Rare Neurological Diseases | ||
| Rare Musculoskeletal Diseases |
|
|
* Note: This table lists representative diseases covered by our services. For research needs related to other diseases, please contact us.
Our Advantages
- Deep Expertise in Rare Neurological Diseases: Specialized scientific and regulatory knowledge tailored to the unique challenges of rare motor and neurological disorder drug development.
- Integrated One-Stop Solution: Seamless coordination of all clinical trial activities under a single provider, eliminating vendor fragmentation and streamlining communication.
- Flexible Support for IITs and ISTs: Comprehensive services tailored to both investigator-initiated and industry-sponsored trials, accommodating diverse research objectives and funding models.
- End-to-End Quality and Compliance: Rigorous quality assurance frameworks ensuring regulatory readiness and adherence to international standards at every stage of development.
At Protheragen, we are committed to accelerating the journey from laboratory innovation to life-changing therapies for patients with rare motor and neurological diseases. Our comprehensive clinical research services span the full spectrum of therapeutic modalities, including small molecule drugs, cell therapies, gene therapies, therapeutic antibodies, therapeutic peptides, and therapeutic proteins. To further streamline your drug development timeline, we also offer complementary preclinical research services, ensuring a cohesive and continuous transition into first-in-human studies. Contact us today to discuss how we can support your clinical development program.
Reference
- Balasubramanian B, Venkatraman S, Myint K Z, et al. Co-clinical trials: an innovative drug development platform for cholangiocarcinoma[J]. Pharmaceuticals, 2021, 14(1): 51.